alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>

                                                                    Exhibit 32.1

     Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the filing of the Quarterly Report on Form 10-Q for the
Quarter Ended June 17, 2003 (the "Report") by ClubCorp, Inc. ("Registrant"), the
undersigned hereby certifies that, to the best of his knowledge or belief:

     1.   The Report fully complies with the requirements of section 13(a) or
          15(d) of the Securities Exchange Act of 1934, as amended, and

     2.   The information contained in the Report fairly presents, in all
          material respects, the financial condition and results of operations
          of Registrant.

                                                /s/ Robert H. Dedman, Jr.
                                                ----------------------------
                                                Robert H. Dedman, Jr.
                                                Chairman of the Board and
                                                Chief Executive Officer
# L_2013218DE.01003001.xml

| 14.8.2013 | DE | Amtsblatt der Europäischen Union | L 218/30 |
| --- | --- | --- | --- |

14.8.2013

DE

Amtsblatt der Europäischen Union

L 218/30

---

Berichtigung der Durchführungsverordnung (EU) Nr. 230/2013 der Kommission vom 14. März 2013 über die Marktrücknahme bestimmter in die Funktionsgruppe „Aroma- und appetitanregende Stoffe“ einzuordnender Futtermittelzusatzstoffe

(
  Amtsblatt der Europäischen Union L 80 vom 21. März 2013
  )

Amtsblatt der Europäischen Union L 80 vom 21. März 2013

Seite 2, Artikel 2 Absatz 3:

anstatt:

„(3)   Mischfuttermittel und Einzelfuttermittel, die aus den in Absatz 1 genannten Futtermittelzusatzstoffen oder den in Absatz 2 genannten Vormischungen hergestellt und entsprechend der Verordnung (EG) Nr. 767/2009 gekennzeichnet wurden, können bis am 10. April 2015 weiter in Verkehr gebracht und verwendet werden, bis die Bestände erschöpft sind.“

muss es heißen:

„(3)   Mischfuttermittel und Einzelfuttermittel, die aus den in Absatz 1 genannten Futtermittelzusatzstoffen oder den in Absatz 2 genannten Vormischungen hergestellt und bis zum 10. April 2015 entsprechend der Verordnung (EG) Nr. 767/2009 gekennzeichnet wurden, können weiter in Verkehr gebracht und verwendet werden, bis die Bestände erschöpft sind.“

---
FILED

August 17, 1998

Cecil Crowson, Jr.

Appellate C ourt Clerk

IN THE COURT OF CRIMINAL APPEALS OF TENNESSEE

AT JACKSON

AUGUST 1998 SESSION

STATE OF TENNESSEE, ) C.C.A. NO. 02C01-9710-CR-00393

)

Appellee ) SHELBY COUNTY

)

v. ) HON. CAROLYN WADE BLACKETT 

) JUDGE

RICKY FULLER, )

) PROBATION

Defendant/Appellant )

FOR THE APPELLANT: FOR THE APPELLEE:

Charles E. Waldman John Knox Walkup

147 Jefferson, Suite 1102 Attorney General & Reporter

Memphis, TN 38103

Douglas D. Himes

Assistant Attorney General 

425 Fifth Avenue North

Nashville, TN 37243-0493

OPINION FILED 

AFFIRMED

JOHN K. BYERS

SENIOR JUDGE
-2-

O P I N I O N

The defendant entered pleas of guilty to possession of cocaine and was

sentenced to serve 45 days and pay a fine of $500.00; possession of marijuana and

was sentenced to serve 45 days and pay a fine of $500.00; violation of the habitual

motor vehicle offender act and was sentenced to serve one year and pay a fine of

$500.00. The two drug sentences were ordered to be served concurrently and the

habitual motor vehicle offender conviction was ordered to be served consecutive

thereto.

The defendant asks that he be placed on intensive probation which the trial

court denied.

The action of the trial judge is so overwhelmingly supported by the record in

this case that writing an opinion is almost frivolous.

The pre-sentence report of the defendant shows seven pages filled with

convictions for drug offenses, various offenses for driving on a revoked license, and

at least one probation revocation. The record further shows a previous conviction

for being a habitual motor vehicle offender.

While on bond for the drug offense subject to this case, the defendant was

convicted for speeding, reckless driving, driving on a suspended license while being

a habitual motor vehicle offender, and leaving the scene of an accident.

There is no need to cite any case or statutory law on the defendant’s behalf

because none will rescue him from his self-imposed dilemma. There is no need to

cite any case or statutory law to support the correctness of the trial judge’s ruling

because the convictions of the defendant speak so loudly on the appropriateness of

the sentences that no citation to authority would enhance the correctness of the trial

judge’s ruling.

The judgment is affirmed. 
-3-

 

John K. Byers, Senior Judge

CONCUR:

 

David H. Welles, Judge

 

Jerry L. Smith, Judge
## United States Court of Appeals FOR THE EIGHTH CIRCUIT

___________ No. 98-1084

___________ Ethridge Dyer; Eloise Dyer, Husband * and Wife, * * Appellants, * * v. * * K. Marcus Poemoceah, M.D.; John D. * Appeal from the United States Alston, M.D., also known as Jack D. * District Court for the Alston; Gravette Medical Associates, * Western District of Arkansas. Ltd; Northwest Arkansas Surgical * Clinic, P.A., * [UNPUBLISHED] * Appellees, * * Tom Crosby, M.D., * * Movant. *

___________ Submitted: February 5, 1999 Filed: March 19, 1999

___________ Before McMILLIAN, LOKEN, and MURPHY, Circuit Judges.

___________ PER CURIAM.1 The Honorable H. FRANKLIN WATERS, United States District Judge for the

Western District of Arkansas. -2- Ethridge Dyer and Eloise Dyer, husband and wife, appeal from the district court’s 1 adverse judgment upon a jury verdict, and its order denying them judgment as a matter of law or a new trial, in their diversity action claiming medical malpractice. After careful review of the record and the parties’ briefs, we affirm for the reasons stated by the district court in its order, and we reject as meritless the Dyers & additional claim of instructional error. For the first time on appeal, the Dyers challenge remarks made by opposing counsel during closing argument; reviewing for plainerror, we conclude that none of the challenged remarks prejudiced any of the Dyers’ substantial rights. See Rushv. Smith , 56 F.3d 918, 922 (8th Cir.) (en banc), cert. denied , 516 U.S. 959 (1995). Accordingly, we affirm. See8th Cir. R. 47B. A true copy.
Attest:
CLER K, U.S. COURT OF APPEALS, EIGHTH CIRCUIT.
# Commission Implementing Regulation (EU) No 303/2013Show full title

Commission Implementing Regulation (EU) No 303/2013 of 27 March 2013 establishing the standard import values for determining            the entry price of certain fruit and vegetables         

        - Previous
        - Next

U.K.

# Commission Implementing Regulation (EU) No 303/2013                     

# of 27 March 2013

# establishing the standard import values for determining the entry price of certain fruit and vegetables

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Council Regulation (EC) No 1234/2007 of 22 October 2007 establishing a common organisation of agricultural                           markets and on specific provisions for certain agricultural products (Single CMO Regulation)(1),                        

Having regard to Commission Implementing Regulation (EU) No 543/2011 of 7 June 2011 laying down detailed rules for the application                           of Council Regulation (EC) No 1234/2007 in respect of the fruit and vegetables and processed fruit and vegetables sectors(2), and in particular Article 136(1) thereof,                        

Whereas:

(1)Implementing Regulation (EU) No 543/2011 lays down, pursuant to the outcome of the Uruguay Round multilateral trade negotiations,                              the criteria whereby the Commission fixes the standard values for imports from third countries, in respect of the products                              and periods stipulated in Annex XVI, Part A thereto.

(2)The standard import value is calculated each working day, in accordance with Article 136(1) of Implementing Regulation (EU)                              No 543/2011, taking into account variable daily data. Therefore this Regulation should enter into force on the day of its                              publication in the *Official Journal of the European Union*,

HAS ADOPTED THIS REGULATION:

# Article 1U.K.

The standard import values referred to in Article 136 of Implementing Regulation (EU) No 543/2011 are fixed in the Annex to                     this Regulation.                  

# Article 2U.K.

This Regulation shall enter into force on the day of its publication in the *Official Journal of the European Union*.                  

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 27 March 2013.

*For the Commission, On behalf of the President*,                           

José Manuel Silva Rodríguez                            

*Director-General for Agriculture and Rural Development*                            

## ANNEXU.K.Standard import values for determining the entry price of certain fruit and vegetables

1

OJ L 299, 16.11.2007, p. 1.                           

2

OJ L 157, 15.6.2011, p. 1.
STATE v. Jonathan Denard BOYCE.

No. 129A06.

Supreme Court of North Carolina.

May 22, 2007.

Benjamin Dowling-Sendor, Assistant Appellate Defender, for Jonathan Denard Boyce.

Thomas J. Keith, District Attorney, for State.

The following order has been entered on the motion filed on the 18th day of May 2007 by Attorney General for Extension of Time to File Brief:

"Motion Allowed. Attorney General shall have up to and including the 26th day of June 2007 to file and serve his/her brief with this Court. By order of the Court in conference this the 22nd day of May 2007."
**Exhibit31.1**

**CERTIFICATION**

 

I, John H.Bullion, ChiefExecutive Officer of Orphan Medical, Inc., certify that:

 

1.             I have reviewed this Quarterly Report on Form10-Q of Orphan Medical, Inc.;

 

2.             Based on my knowledge, this report does notcontain any untrue statement of a material fact or omit to state a materialfact necessary to make the statements made, in light of the circumstances underwhich such statements were made, not misleading with respect to the periodcovered by this report;

 

3.             Based on my knowledge, the financialstatements, and other financial information included in this report, fairlypresent in all material respects the financial condition, results of operationsand cash flows of the registrant as of, and for, the periods presented in thisreport;

 

4.             The registrant’s other certifying officer(s)and I are responsible for establishing and maintaining disclosure controls andprocedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for theregistrant and have:

 

a)             Designed such disclosure controls andprocedures, or caused such disclosure controls and procedures to be designedunder our supervision, to ensure that material information relating to theregistrant, including its consolidated subsidiaries, is made known to us by otherswithin those entities, particularly during the period in which this report isbeing prepared;

 

b)            Evaluated the effectiveness of the registrant’sdisclosure controls and procedures and presented in this report our conclusionsabout the effectiveness of the disclosure controls and procedures, as of theend of the period covered by this report based on such evaluation; and

 

c)             Disclosed in this report any change in theregistrant’s internal control over financial reporting that occurred during theregistrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarterin the case of an annual report) that has materially affected, or is reasonablylikely to materially affect, the registrant’s internal control over financialreporting; and

 

5.             The registrant’s other certifying officer(s)and I have disclosed, based on our most recent evaluation of internal controlover financial reporting, to the registrant’s auditors and the audit committeeof the registrant’s board of directors (or persons performing the equivalentfunctions):

 

a)             All significant deficiencies and materialweaknesses in the design or operation of internal control over financialreporting which are reasonably likely to adversely affect the registrant’sability to record, process, summarize and report financial information; and

 

b)            Any fraud, whether or not material, thatinvolves management or other employees who have a significant role in theregistrant’s internal control over financial reporting.

 
| Date:  | November 9, 2004 |                    | /s/ John H. Bullion |   |
|--------|------------------|-------------------------|---------------------|--------|
|   |             | Chief Executive Officer |                |
|   |             |                    |                |

 

1

----
EXHIBIT 10-(j)
     
Panax to Acquire Novel Product used for Clearing the Colon prior to
                          Colonoscopy

     NEW YORK, NY; January 15, 1997 -- Panax Pharmaceutical Company Ltd.
[NASDAQ: PANX, PANXU, PANXW] today announced that it has signed a letter of
understanding to acquire the world-wide exclusive rights to manufacture, sell 
and sublicense a novel preparative tablet product for clearing the colon 
prior to colonoscopy.  During a colonoscopy, the doctor views the colon 
through a camera to screen for polyps or pre-cancerous tissue.  In order to 
be able to perform the procedure, the colon must be completely cleared of 
fecal matter.  Currently, the colon is cleared through the consumption of 
unusually large volumes of liquid containing  polyethylene glycol (PEG) or 
noxious tasting solutions of salts which induce diarrhea.   The existing  
products are routinely difficult to tolerate.

     Clinical studies on over 300 patients suggests that Panax's 
investigational purgative tablet was as effective, but better tolerated, 
than two leading commercial liquid products.  Panax plans to conduct 
confirming phase II/III clinical trials and anticipates filing a  New Drug 
Application (NDA) with the Food and Drug Administration (FDA) within 18 to 24
months.

     Rights to the product have been acquired from Craig Aronchick, MD for a
royalty on product sales, a warrant to purchase 250,000 shares of Common Stock
and a cash payment of $100,000.  Additional warrants and cash payments are based
on progress in commercializing the product.  Dr. Craig Aronchick is an attending
gastroenterologist and Head of the Endoscopy Unit at Pennsylvania Hospital in
Philadelphia, and an Associate Professor of Medicine at Jefferson Medical
College.  Dr. Aronchick will consult for the Company and serve as an advisor
during the product development.

     Dr. Taffy Williams, President & Chief Executive Officer, of Panax stated
that "we look forward to working with Dr. Aronchick to complete the development
of this important product.  We believe that our tablets will offer distinct
advantages over current commercial purgative preparations which require the
patient to consume as much as one gallon of a liquid containing PEG. 
Gasteroenterologists conducted over 4.5 million colonoscopies in just the United
States in 1992 and it is estimated that this number could double by the year
2000.  The market for the product may be even larger when other potential 
markets such as cleansing of the colon prior to X-ray studies or surgery are 
addressed. A  lower dosage form may also be useful in the relief of 
constipation."

     Panax Pharmaceutical Company Ltd. is engaged in the research and
development of pharmaceutical products.
EXHIBIT 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Chinawe.com Inc. (the ‘‘Company’’) on Form 10-KSB for the period ending December 31, 2007, as filed with the Securities and Exchange Commission on the date hereof (the ‘‘Report’’), I, Vivian Chu, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. ss.1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

| |     |                                                                                                                      
| | --- | ---------------------------------------------------------------------------------------------------------------------
| | (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

| |     |                                                                                                                                                      
| | --- | -----------------------------------------------------------------------------------------------------------------------------------------------------
| | (2) | The information contained in the Report fairly represents, in all material respects, the financial condition and result of operations of the Company.

/s/ Vivian Chu
Chief Financial Officer

June 17, 2008

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Chinawe.com Inc. and will be retained by Chinawe.com Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

---
In the Matter of J.S.B., et al.

No. 269P07.

Supreme Court of North Carolina.

June 11, 2007.

Tobias S. Hampson, Raleigh, for Mother.

Twyla George, Gastonia, for Mecklenburg County DSS.

Jeannie Brown, Pili Fleming, Charlotte, for Guardian ad Litem.

Prior report: ___ N.C.App. ___, 644 S.E.2d 580.

The following order has been entered on the motion filed on the 7th day of June 2007 by Respondent (Mother) for Temporary Stay:

"Motion Denied by order of the Court in conference this the 11th day of June 2007."
**EXHIBIT
      32.1**








Certification


Pursuant
      to Section 906 of the Sarbanes-Oxley Act of 2002


(Subsections
      (a) and (b) of Section 1350, Chapter 63 of Title 18, United States
      Code)





Pursuant
      to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of
      Section 1350, Chapter 63 of Title 18, United States Code), I, Dan R. Lee,
      Chairman, President and Chief Executive Officer of Microtek Medical Holdings,
      Inc., a Georgia corporation (the “Company”), do hereby certify, to the best of
      my knowledge, that:





This
      Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 (the “Form
      10-Q”) of the Company fully complies with the requirements of Section 13(a) or
      15(d) of the Securities Exchange Act of 1934 and information contained in this
      Form 10-Q fairly presents, in all material respects, the financial condition
      and
      results of operations of the Company.








August
                9, 2007
            /s/
                Dan R. LeeDan
                R. LeeChairman,
                President and Chief Executive
                Officer
<PAGE>
                                                                      EXHIBIT 11

                       STAR BUFFET, INC. AND SUBSIDIARIES
                            COMPUTATION OF EARNINGS
                                   PER SHARE

<TABLE>
<CAPTION>
                                                           FIFTY-THREE    FIFTY-TWO     FIFTY-TWO
                                                           WEEKS ENDED   WEEKS ENDED   WEEKS ENDED
                                                           JANUARY 31,   JANUARY 25,   JANUARY 26,
                                                              2000          1999          1998
                                                           -----------   -----------   -----------
<S>                                                        <C>           <C>           <C>
BASIC EARNINGS PER SHARE:
Net income...............................................  $1,425,000    $2,435,000    $2,699,000
                                                           ----------    ----------    ----------
Weighted average number of common shares outstanding
  during the period......................................   2,950,000     4,601,000     3,515,000
                                                           ----------    ----------    ----------
Basic earnings per share.................................  $     0.48    $     0.53    $     0.77
                                                           ----------    ----------    ----------

DILUTED EARNINGS PER SHARE
Net income...............................................  $1,425,000    $2,435,000    $2,699,000
                                                           ----------    ----------    ----------
Weighted average number of common shares outstanding
  during the period......................................   2,950,000     4,601,000     3,515,000
                                                           ----------    ----------    ----------
Incremental common shares attributable to outstanding
  stock options..........................................          --            --        13,000
                                                           ----------    ----------    ----------
                                                            2,950,000     4,601,000     3,528,000
Diluted earnings per share...............................  $     0.48    $     0.53    $     0.76
                                                           ----------    ----------    ----------
</TABLE>
Exhibit 99.1



CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the quarterly report of The Sports Authority, Inc. (the Company) on Form 10-Q for the period ended May 3, 2003 as filed with the Securities
and Exchange Commission on the date hereof (the Report), I, Martin E. Hanaka, Chief Executive Officer of the Company, certify that to the best of my knowledge:



|(1) |  | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|--- |  | ---------------------------------------------------------------------------------------------------------------------



|(2) |  | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|--- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------



/s/ MARTIN E. HANAKA

---

Martin E. Hanaka

Chairman
and

Chief Executive Officer



June 17, 2003